| 摘要 |
A use of an R'-Glu'Trp-R" dipeptide or a pharmaceutically acceptable salt thereof in the treatment of a pathologic condition involving neovascularization. Preferably, the dipeptide is of the formula L-Glu-L-Trp, and the pathologic conditions may result from an hemangioma, a vascularized malignant tumor or vascularized benign tumor, post-recovery cerebrovascular accident, head trauma, restenosis following angioplasty; or heat or cold trauma. The dipeptide is administering intramuscularly or intranasally to the subject in a dosage amount of from about 0.5 mg per 1 kilogram body weight to about 1 mg per 1 kilogram body weight, over a period of 1 day to about 30 days.
|
